Sab Biotherapeutics, Inc. · NASDAQ:SABS
Commodore Capital LP reported a 9.90% stake in Sab Biotherapeutics, Inc. (Schedule 13G/A)
Filed Aug 14, 2026
Commodore Capital LP reported a 9.90% stake in Sab Biotherapeutics, Inc., 8,948,170 shares, as a passive investor. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 9.90%
- Shares
- 8,948,170
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Commodore Capital LP | 9.90% | 8,948,170 |
| Commodore Capital Master LP | 9.90% | 8,948,170 |
| Robert Egen Atkinson | 9.90% | 8,948,170 |
| Michael Kramarz | 9.90% | 8,948,170 |
Source
Related
- Sab Biotherapeutics, Inc.
- Commodore Capital LP
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G · Commodore Capital LP · Oct 3, 2025
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G/A · Caligan Partners LP · Aug 14, 2026